What can we help you find?
In a Pharmacy Times Continuing Education Supplement, Elena E. Perez, MD, PhD, examined the evolution of immunoglobulin [Ig] in its treatment use, including patient populations and potential adverse events.
New approach involves treating patients with a high dose factor VIII concentrates along with emicizumab, a modification of the standard immune tolerance induction.
Specialty pharmacists play an important role in the selection of immunoglobulin G products and optimizing therapy for patients.
Pharmacist Education Is Key to Helping Patients With Chronic Inflammatory Demyelinating Polyneuropathy
At the Asembia Specialty Pharmacy Summit 2019, a panel of experts educated audience members about chronic inflammatory demyelinating polyneuropathy.
Galcanezumab-gnlm (Emgality, Eli Lilly) is the first calcitonin gene-related peptide antibody approved for both migraine and episodic cluster headache in adults.
Hizentra may treat patients with chronic inflammatory demyelinating polyneuropathy.
Real-world dose adjustments occurred in patients with primary immunodeficiency who switched from intravenous immunoglobulin to subcutaneous immunoglobulin 20%, with resulting implications for payers, patients, and plasma collection and supply.
The first report of long-term (3-year) stabilization of Alzheimer's disease symptoms with IVIG, including no decline on measures of cognition, memory, daily functioning and mood, was recently reported at the Alzheimer's Association International Conference 2012 in Vancouver.
This home delivery pharmacy focuses in intravenous immune globulin programs to improve care and outcomes for patients.
When patients have immunodeficiency conditions that require immunoglobulin therapy (IVIG), clinicians must consider carefully which IVIG product will have the fewest adverse effects and the highest level of efficacy.